Plain-English translation of NCT03362619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy approach called engineered immune effectors (EIEs) for people with advanced or recurrent cervical cancer. These are specialized immune cells that are grown in a lab to recognize and attack cancer cells. The study will evaluate whether multiple infusions of this treatment are safe and effective for patients with cervical cancer.
Most cervical cancers are caused by human papillomavirus (HPV) infection, and current treatments like surgery, radiation, and chemotherapy don't work for everyone. This trial exists to see if the new treatment — which harnesses the body's own immune system to target HPV-related cancer cells — might offer hope to patients whose cancer has advanced or returned.
If you join this trial, you will receive multiple infusions of engineered immune cells that have been grown specifically to target your cervical cancer. The study will monitor your safety and how your cancer responds to the treatment through regular medical visits, blood tests, and imaging. The trial is still recruiting participants, so the exact schedule and duration would be discussed with the research team when you enroll.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~20 participants
Started
June 2026
Primary completion
July 2026
Age range
10 Years – 80 Years
Sex
Female only
Last updated on clinicaltrials.gov in August 2026.